CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that

Read the full 282 word article

User Sign In